{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
Hepadial by Unicler
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Dimecrotic acid is a choleretic agent with spasmolytic properties. It is obtained by reaction of resorcinol with acetoacetate to give 4-methyl-7-hydroxycoumarin. It is indicated for the treatment of hepato-digestive insufficiency and its manifestations. It shouldn’t be used in case of blockage of bile ducts, severe liver failure and severe renal impairment. Diarrhea may be associated with high doses of dimecrotic acid.
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M018
(2024)
Source URL:
First approved in 2024
Source:
M018
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Pentasodium aminotrimethylene phosphonate (Dequest® 2006) is a general purpose, cost-effective scale inhibitor based on amino tri methylene phosphonic acid pentasodium salt. Dequest® 2006 provides corrosion inhibition with zinc and phosphates and is a good chelant. In cosmetics, pentasodium aminotrimethylene phosphonate is used as an emulsifier.
Status:
Possibly Marketed Outside US
Source:
ANDA205291
(2024)
Source URL:
First approved in 2024
Source:
ANDA205291
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Laurylsulfonic acid is anionic surfactant, used in cosmetics.
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2024
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M003
(2024)
Source URL:
First approved in 2024
Source:
M003
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Nigericin is an antibiotic derived from Streptomyces “Nig-1”. It is the potassium ionophore and H+/K+ exchanger. It is shown to be highly effective as an ionophore for Pb(2+). Thus, nigericin may be more useful than monensin in the treatment of Pb intoxication. Nigericin induced mitochondrial membrane hyperpolarization. Malignant characteristics of human glioma cells were markedly suppressed by nigericin treatment in vivo. Nigericin induces cell death and promotes the maturation and release of IL-1beta in lipopolysaccharide (LPS)-primed monocytes and macrophages. The mechanism of induction of apoptosis by nigericin is most probably to decrease intracellular pH.
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)